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Abstract 
Project 1 
The ‘lymphoid stress surveillance’ hypothesis proposes a role for γδ T cells in in the 
detection of epithelial stress. TCR mediated recognition of stress ligands by γδ T cells is 
currently poorly understood. This project aimed to characterise the molecular mechanisms 
of the interaction between of the Vδ1+ MAU γδ TCR with the ephrin receptor EphA2. EphA2 
is a major target for anti-cancer treatments, and is upregulated on a range of epithelial 
tumours, a tissue enriched with Vδ1+ γδ T cells. 
We show that EphA2 activates MAU expressing JRT3.5 cells in a TCR dependant manner, by 
receptor downregulation and phosphorylation of key TCR proximal signalling proteins. It 
was also found that A-ephrins on the surface of the T cell are essential for the activation of 
JRT3 MAU by EphA2. 
Project 2 
Multiple Myeloma (MM) is an incurable haemopoietic malignancy, characterised by the 
accumulation of malignant plasma cells in the Bone Marrow (BM). MM cells express a group 
of proteins called Cancer Testis Antigens (CTA) whose expression is limited to the immune-
privileged site of the testis in healthy adults. CTA specific CD8+ T cells in MM patients display 
poor in vivo effectiveness, and are poorly understood.  
Immuno dysregulation is a common occurrence in MM, with a dysregulation in the 
distribution and expression of key chemokines involved in lymphocyte trafficking such as 
CXCR3 and CXCR4, which may be a defensive mechanism by the tumour to protect against 
CTA specific T cells.  
This project aimed to characterise the chemokine receptor expression on CTA specific CD8+ 
T cells in MM patients, and it was discovered that MM patients have a reduction in CXCR3 
and CXCR4 expression on CD8+ T cells in the blood, and that the chemokine receptor 
expression pattern of different viral specific CD8+ T cells  are affected uniquely by MM. 
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PROJECT 1 
Investigating Immune Recognition of an Epithelial 
Stress Antigen by Human γδ T Cells 
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Introduction 
γδ T Cells  
γδ T cells represent an unconventional subset of T cells which express a γδ TCR at the cell 
surface, a heterodimer consisting of one γ and one δ chain. In contrast, conventional αβ T cells 
express an αβ heterodimer. αβ T cells form the majority of the cellular arm of the adaptive 
immune system, and act via recognition of peptidic antigen presented in the context of MHC 
(Major Histocompatibility Complex) molecules. Following this recognition, and the subsequent 
binding of co-stimulatory molecules, a complex signalling cascade is initiated from the TCR/CD3 
complex, initially propagated by tyrosine phosphorylation of a series of signalling molecules. 
This culminates in the initiation of specific effector functions, such as the production of pro-
proliferative cytokines, and cell mediated killing1. 
The genes which encode for all four of the TCR chains (α, β, γ and δ) were discovered 
simultaneously in the 1980s 2, and yet specific, in depth knowledge of the function and activity 
of γδ T cells is severely lacking compared to αβ T cells. γδ T cells emerged at the same 
evolutionary time point as αβ cells, 400-500 million years ago3, and are conserved in all 
vertebrates. This suggests that they may have evolved similarly complex functions as αβ T cells, 
and may perform complementary roles in the vertebrate immune system. Indeed, γδ T cells 
have been shown to have key roles in immuno-protection, immuno-regulation, tumour 
recognition and recognition of cellular stress (Reviewed in 4). 
The Lymphoid Stress Response Compartment 
The term ‘immune surveillance’ could be defined as the constant monitoring of host cells by the 
immune system to detect early signs of infection, transformation and other such insults. 
Conventional myeloid-based immune surveillance involves the recognition of a range of 
pathogen associated molecular patterns (PAMPs) by germline-encoded pattern recognition 
receptors (PRRs) on the surface of innate cells5. PAMPs are derived from a broad spectrum of 
sources, both microbial and viral in origin, and although PAMPs are not generally specific to a 
particular pathogen, they are often indicative of an infection. In addition, damage associated 
6 
molecular patterns (DAMPs), can also activate innate immune cells. Examples of such molecules 
include ureate and ATP, which are released from dying cells6. 
After encountering such antigens, myeloid cells migrate to secondary lymphoid tissue and 
present antigen to naive lymphocytes, initiating a specific immune response against the 
pathogen. This process culminates in an expansion of antigen specific populations of 
lymphocytes, which then migrate to the damaged tissues. This process of clonal expansion, 
differentiation and migration takes a significant amount of time to achieve, in the meantime 
leaving the host vulnerable to the spread and advancement of the infection (Figure 1). 
 
Figure 1: The Role of the γδ TCR in Tissue Stress Surveillance 
(Top) Conventional, microbe-initiated activation of the local, myeloid cell-mediated innate response and its 
communication of information to the adaptive T and B cell compartments. (Bottom) The lymphoid stress-
surveillance response is initiated by many forms of non-microbial as well as microbial stress that upregulate surface 
expression of ligands for γδ TCR or for NKG2D, to which the T cells are competent to respond because of other 
receptor-ligand ‘‘context interactions’’. The question mark denotes that the full scope of this stress-surveillance 
response has yet to be determined. 
Figure and Caption from 
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In addition to these myeloid cells, unconventional lymphoid subsets are able to make a key 
contribution to immune surveillance of stressed tissue, before the adaptive immune system can 
take effect. These unconventional lymphoid subsets, such as NK and γδ T cells, are able to 
recognise a set of ‘stress ligands’ which the innate myeloid cells cannot. Examples of such 
molecules are the MHC Class I Like molecules (e.g. MICA7), which are recognised by the NKG2D 
receptor4,8. Once these cells encounter stress antigens via their receptors (e.g. NKG2D or TCR) 
they produce a ‘lymphoid stress surveillance response’, in which they respond directly to 
stressed tissue by processes such as cytolysis7. These local effector functions are unlikely to 
completely eradicate an infection or tumour, due to their lack of adaptive ability. This 
‘lymphoid stress surveillance’ hypothesis does however ascribe unconventional T cells a role in 
maintaining tissue integrity and limiting any development or spread while initiating and 
integrating with a downstream adaptive immune response. This interaction is likely to be 
achieved through many actions, such as antigen presentation and the production of cytokines 
and chemokines to promote the homing of lymphocytes to the site of stress7 (Figure 1). The 
‘lymphoid stress surveillance’ hypothesis therefore proposes a rapid layer of protection to 
cellular stresses through the actions of specific unconventional lymphocyte subsets, which 
simultaneously promote and shape a specific downstream adaptive response. 
Arguably the prototypic unconventional lymphocyte is the γδ T cell, which can exist as resident, 
pre-expanded populations at distinct (and often epithelial) anatomical sites, potentially making 
them ideal candidates for a role in the rapid recognition of both microbial and non-microbial 
stresses. Given the importance of the proposed role for γδ T cells in the lymphoid stress 
surveillance response, it is important to achieve a greater understanding of the molecular basis 
of γδ T cell recognition, specifically the role of the TCR, in the context of the ‘lymphoid stress 
surveillance’ hypothesis. 
γδ T Cell Subsets, Localisation and Ligand Recognition 
γδ T cell subsets are localised to discrete anatomical sites, where different tissues are enriched 
with γδ T cells exhibiting particular V-region usages. This is most apparent in the mouse, in 
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which V-region usage can be reliably mapped to distinct sites4 (Figure 2). One such association 
is the Vγ5 Vδ1 subset, expressed by >90% of mouse skin DETC (dendritic epidermal T cells)9,10. 
 
Figure 2: Murine Localisation of γδ T cell Subsets 
In humans, the tissue associations of γδ T cell subsets are more poorly understood, with the 
best characterised being the Vδ2+  subset, which comprises 2 to 5% of CD3+ cells in the human 
peripheral blood (PB)4, the vast majority of which dispay the pairing of the Vδ2 chain with the 
Vγ9 chain (Vγ9 Vδ2 cells)11. 
Although the molecular basis of Vγ9 Vδ2 T cell recognition is unclear, they display broad anti-
tumour and anti-infectious reactivity. They have been shown to be activated in a TCR 
dependant manner by low-molecular mass, non-peptidic phospho-antigens (pAg) which are 
intermediate metabolites from the mevalonate isoprenoid pathway. One such metabolite is 
isopentenyl PPi (IPP)12, which is found in all host cells and is essential for mammalian survival13. 
The most potent pAg activator of Vγ9 Vδ2 cells characterised so far is the bacterial-specific 
intermediate hydroxy-methyl-butenyl pyrophosphate (HMBPP), which has a 1000 fold stronger 
stimulating activity of Vγ9 Vδ2 cells than IPP14. Vγ9 Vδ2 γδ T cells are also capable of 
recognising and killing a range of myeloma and lymphoma cells in vitro in a TCR dependent 
manner, such as the Daudi15 and K56216 cell lines. Effectiveness of responses to these cells was 
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increased by the use of amino bisphosphonates (such as Zoledronate) which increase the 
accumulation of IPP in cells due to inhibition of an enzyme downstream of IPP in the isoprenoid 
pathway, farnesyl pyrophosphate synthase (FPPS)17. These data suggest Vγ9 Vδ2 cells can 
recognise both host and microbial pAg, and raises questions as to whether this involves an 
antigen presenting molecule. 
In addition to data on pAg recognition, some data suggest that Vγ9 Vδ2 cells can recognise 
whole protein antigens via their TCR, such as the mitochondrial F1-ATPase, which is ectopically 
expressed at the cell surface in a range of cancers18, and may be involved in the processing and 
presentation of pAgs from non-antigenic precursors (such as triphosphoricacid 1-adenosin-5’-
ylester 3-(3-methylbut-3-enyl) ester (ApppI))19. There is also evidence of direct binding with 
heat shock proteins20, as well as viral proteins21.  
Non-peripheral blood γδ T cells (typically Vδ2- subsets) occupy other sites of the body; for 
example, use of the Vδ1 chain is greatly increased at epithelial surfaces. These Vδ1+ cells 
comprise part of the intraepithelial lymphocyte (IEL) compartment, and make up 70-90% of 
epithelial γδ T cells in humans22. The molecular basis of Vδ1+ epithelial ligand recognition is 
unclear, but there is some evidence to suggest that the Vδ1+ subset in humans recognises MHC 
like molecules, such as CD1c, an MHC-like molecule which presents lipids to T cells23, and the 
MHC class I like proteins MIC A and B, which are ligands for the invariant NK receptor NKG2D, 
and are expressed in response to cellular stress, such as in both infected and transformed 
epithelium24,25. 
The antigens discussed so far for each of the two subsets share a common theme, in that they 
have been shown to be associated with both infection and transformation. This, combined with 
the fact that γδ T cell subsets are distributed to discrete anatomical sites according to their 
chain usage, has been used to suggest that γδ T cells play a role in recognition of a limited 
number of tissue associated stress antigens, detected by the limited use of V regions at these 
distinct anatomical sites26. 
The exact molecular basis of γδ TCR/ligand interactions underlying the cellular interactions 
discussed above is poorly understood, and many of the TCR ligands remain unidentified. In 
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cases where ligands have been identified, there is little evidence of direct binding available, for 
example attempts to crystallise Vγ9 Vδ2 TCRs with pAg have failed27. Some have argued for 
direct binding between a Vδ1+ γδ TCR and MICA, although the surface plasmon resonance (SPR) 
data is unconvincing28. It is also important to broaden the understanding of the biological 
context of these interactions, for example how ligand presentation and upregulation is 
associated with processes such as transformation and infection. 
Clinical Manipulation of γδ T Cells 
There is a growing body of evidence supporting the potential significance of γδ T cells in the 
prevention and treatment of various cancers29. γδ T cell-based immunotherapies are 
particularly attractive as they circumvent the requirement for MHC restriction demanded by 
conventional αβ based strategies. Promising results from phase I and II clinical trials has fuelled 
a growing interest in the development of γδ based T cell therapies for cancers 33-35. 
In mice, γδ T cells have been shown to play an important role in the protection from 
carcinogenesis. TCRδ-/- mice have a greater risk of chemically-induced skin carcinoma30, and 
colorectal carcinoma31 than γδ T cell-positive controls. More recently, IL-17 producing γδ T cells 
have been shown to play a pivotal role in the effectiveness of chemotherapy induced anti-
cancer immune responses32. Research is not limited to mouse models however; as there are 
currently three phase I clinical published using the Vγ9 Vδ2 peripheral blood subset, showing 
promising results; in each case improved clinical outcomes correlate with the expansion of Vγ9 
Vδ2 T cells33-35. There are also studies showing the importance of the less well characterised 
Vδ2- subset of γδ T cells in cancer prevention, as immunocompromised transplant patients who 
have an expansion of Vδ2- γδ T cells have a decreased risk of post-transplant malignancies in 
the 6 years following surgery36,37. 
These trials and investigations suggest that there is considerable potential to exploit the 
tumour surveillance and anti-tumour properties of γδ T cells in the clinic. Ultimately, however, 
the molecular basis of target cell recognition by γδ TCRs is unclear, and advances in this area 
are important if we are to understand the mechanism behind their involvement in anti-tumour 
effects, and potentially manipulate these mechanisms to develop novel cancer treatments. 
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Expansion of Dually Reactive Vδ2- γδ T Cells Following Renal Transplant 
In 2005, Halary et al. reported the expansion of Vδ2- (Vδ1, Vδ2 and Vδ5) γδ T cells in the blood 
of immunocompromised renal transplant patients, following acute infection with CMV11. In 
these patients, the circulating γδ T cell repertoire was increased from 5% to 50% of total PB T 
cells, and this increase was directly correlated to the resolution of viremia11. This expansion of 
Vδ2- cells was also linked to a decrease in susceptibly to post transplant cancers which are 
favoured by the immunocompromised status of the patients37. 
Clones were generated from the Vδ2- γδ cells which demonstrated strong reactivity to CMV-
infected cells in vitro by a TNFα release assay, in an MHC class I-and NKG2D-independent 
manner. Individual Vδ2- clones also showed strong reactivity to different subsets of cancer cell 
lines, such as HT29 and 293T, as well as CMV infected fibroblasts11. These interactions were 
suspected to be TCR dependent, as the use of anti CD3/ Cδ antibodies to block TCR engagement 
prevented reactivity, and the γδ TCR was down regulated following activation, a phenomenon 
typical of TCR mediated interactions11. These suspicions were subsequently confirmed by 
transfection experiments, in which the TCR genes for the dual reactive clones were transfected 
into JRT3 cells (a leukemia cell line, with a mutation in the β chain locus of the TCR preventing 
αβ TCR surface expression). This transfection conferred tumour reactivity to these previously 
TCR negative cells. 
These findings led to the hypothesis that these γδ T clones were recognising stress ligands 
induced by both viral infection and transformation, via their γδ TCRs. In order to understand 
and ultimately manipulate these interactions, identification of the ligands recognized was 
required. 
The Identification of Target TCR Ligands for Vδ2- γδ T Cells 
Subsequent unpublished studies from the laboratories of Julie Déchanet-Merville and David 
Vermijlen have shown that there appears to be considerable diversity in the pattern of cancer 
cell lines these Vδ2- γδ T cell clones were recognising. Three of these clones were selected for 
further study, designated MAU, LES and POS4. The reactivity of these clones was confirmed by 
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TCR transfection experiments, in which the TCR genes from each clone were transfected into 
JRT3 cells (Appendix Figure 1A). The LES clone has the TCR chain usage of Vγ4 Vδ5, MAU has 
Vγ9 Vδ1 and POS4 has Vγ8 Vδ1. 
In order to determine the ligands for the two clones LES and MAU, an antibody blocking screen 
was conducted by immunising BALB/c mice with the activatory HT29 cell line and CMV infected 
fibroblasts. Two antibodies discovered in this screen (6G8 for Mau and 2E9 for LES) were shown 
to block reactivity (of LES an MAU respectively) to activatory cell lines. In each case the 
antibody stained the surface of the activatory cell and also blocked reactivity in a TCR 
dependent manner (i.e. 6G8 did not block LES activation and 2E9 did not block MAU reactivity) 
(Appendix Figure 1A). Based on these observations, a reasonable working assumption was that 
the ligands for the blocking antibodies 2E9 and 6G8 would be the TCR ligands for LES and MAU 
respectively. 
The 2E9 and 6G8 blocking antibodies were then used in co-immunoprecipitation experiments to 
isolate their respective ligands (Appendix Figure 1B). The molecules co-immunoprecipitated 
from activatory cell lysates were analysed by mass spectrometry, and were identified as EPCR 
(Endothelial Protein C Receptor) and EphA2 (Ephrin Receptor A2) for 2E9 and 6G8 respectively. 
The simplest explanation considering the evidence thus far was that these molecules were the 
ligands for the LES and MAU γδ TCRs, respectively. 
EPCR is the receptor for activated protein C, and is involved in inhibition of coagulation and 
endothelial barrier protection. EPCR is expressed on endothelial cells38, targets for CMV 
infection in vivo, and is also over-expressed in epithelial tumours39. EphA2 exhibits similar 
characteristics, and will be discussed in detail in the following sections of this report.  
The most striking feature of these two potential ligands was that they are not only expressed 
on cells infected by CMV in vivo, but also upregulated on transformed epithelial cells. In each 
case they confirm the central hypothesis that ligands would be present on CMV infected and 
transformed cells. This raises the possibility that these molecules act as major targets of γδ T 
cell stress surveillance, or are prototypic of the type of ligand recognised in this context. 
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EphA2: a Target for Epithelial Stress Surveillance γδ T Cells? 
EphA2 is a 130kDa transmembrane protein, belonging to the largest family of tyrosine kinase 
receptors (RTKs), the ephrin receptors. Ephrin receptors have a diverse range of physiological 
roles, including in embryonic and nervous system development and angiogenesis40. The 
cognate ligands of the ephrin receptors are the ephrins, which can be separated into two 
groups: A and B ephrins. B-ephrins are transmembrane proteins, with a small cytosolic region. 
A-ephrins are small proteins, of around 200 amino acids, which are tethered to the cell surface 
via glycophosphatidylinositol (GPI) anchors, and so do not possess either transmembrane or 
cytosolic regions. GPI anchors are a post translational modification added to the C-terminal end 
of a diverse group of proteins during production and processing, and act as a crucial 
determinant of signalling activity and localisation41. EphA2 has been shown to bind only to A-
ephrins, which are GPI linked. In contrast, EphA4 binds all A-type ephrins like EphA2, but also all 
transmembrane B-ephrins as well42. 
EphA2 is reported to play an integral role in the formation and progression of many 
cancers40,41,43, and is abundantly overexpressed in many solid tumours40. Unlike other members 
of the ephrin receptor family, which are limited to expression during development, EphA2 is 
primarily located on adult epithelial cells44, where it is suggested to play roles in the regulation 
of cell growth, survival, migration, and angiogenesis (reviewed in 45). EphA2 is usually tightly 
confined to surfaces of cell-cell contacts, and is heavily dependent on E-cadherin for correct 
localisation and ligand interactions43.  
EphA2’s complex role in the progression and maintenance of malignancies is poorly 
understood, but seems to depend heavily on cell type and micro-environment46. It is suggested 
that EphA2 usually provides a tumour suppressor function, whereby it negatively regulates 
tumour growth upon binding with its ligands, which results in receptor phosphorylation. Upon 
transformation, EphA2 displays dramatic alterations in subcellular localisation and is located in 
membrane ruffling in aggressive tumour cells47. These unstable cell-cell contacts are thought to 
prevent effective ligand:receptor interactions, and hence promote the growth of the tumour47. 
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This is supported by the finding that EphA2 over expressed on tumours is usually found in an 
unphospohorylated form, suggesting limited interactions with ligand48. 
EphA2 has become a major target for cancer immunotherapy, and a large body of research is 
dedicated to delivering such strategies. EphA2’s over-expression in a range of solid cancers 
makes it a very attractive therapeutic target (reviewed in 40). There are currently two broad 
approaches being investigated for the clinical targetting of EphA2. The first is the use of EphA2 
as a target for delivery of exogenous anti-cancer compounds and novel chimeric antigen 
receptors (CAR). For example, use of bacterial toxins bound to ephrinA1 have shown promising 
results, enabling them to be targeted to bearing tumours 49. A second approach is to directly 
manipulate and inhibit the transforming properties of EphA2 to treat cancers, such as the use 
of specific mAbs which are able to bind EphA2 and induce receptor phosphorylation and 
downregulation, restoring tumour suppressive functions50. 
Clearly the close association of EphA2 expression to the establishment and progression of 
epithelial tumours, and association with poor prognosis, increased metastasis and decreased 
survival (reviewed in 40) has established it as a key cancer therapeutic target. It is therefore 
interesting to speculate that γδ T cells may have evolved to target EphA2 for precisely the same 
reasons, as part of their role in surveillance of epithelial stress in the context of the ‘lymphoid 
stress response’ hypothesis. In order to explore this possibility further, this project aims to 
investigate the molecular basis of the interaction between EphA2 and MAU. 
The Molecular Basis of EphA2 Recognition by the Mau γδ T Cell 
A molecular understanding of EphA2 recognition by MAU is essential to fully appreciate its 
potential significance in lymphoid stress surveillance. Surface plasmon resonance (SPR) analysis 
has shown no observable binding between MAU TCR and EphA2 when immobilised on a 
BIACore chip (C. R. Willcox, unpublished observations). This interesting finding suggested that 
the interaction between MAU TCR and EphA2 may be too weak to detect by SPR, as is the case 
for the well documented and physiologically vital interaction between the CD4 ectodomain and 
class II MHC molecules51. Despite this potentially weak binding, previous evidence also strongly 
supports the direct role of the TCR in MAU activation by EphA2, such as anti CD3 mAb blocking 
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experiments, TCR downregulation following activation and the fact that transfection of MAU 
TCR genes confers EphA2 reactivity to JRT3 cells. In contrast, EPCR and LES were observed to 
have a binding affinity of 87μM, similar to that of αβ TCR/MHC interactions (Willcox C. R, et al. 
unpublished), confirming that LES is able to directly bind to EPCR, an interaction sufficient to act 
as the initiator of signalling. 
This potentially weak binding affinity between EphA2 and MAU TCR suggested that the 
interaction between EphA2 and MAU bearing cells may not occur in isolation, and that other 
co-receptors may be involved. As plate bound EphA2 has been shown to be sufficient to 
activate MAU cells, attention should first be drawn to the T cell surface for the search for these 
molecules. Likely candidates are the A-type ephrins, the cognate ligands for EphA2. A-ephrins 
are present on the surface of Jurkat cells52, and are capable of reverse signalling (i.e. signalling 
into the T cell) after interacting with EphA253, and so could potentially play a role in 
supplementing signalling through the TCR and ultimately lead to T cell activation. 
This suggestion raises questions as to how GPI-linked proteins may initiate signalling in T cells, 
as the exact mechanism by which these proteins signal is not yet fully understood. Because GPI-
linked proteins lack a transmembrane and cytosolic region, they cannot signal in a conventional 
way, for example via phosphorylation of cytosolic tyrosine residues. It has been suggested that 
GPI-linked ephrins signal via the recruitment of other transmembrane proteins with signalling 
potential54. These interactions are likely to take place in lipid rafts, discrete micro-domains of 
the cell surface to which GPI-anchored proteins commonly localise. Lipid rafts have been shown 
to have key roles in vesicular trafficking and cell signalling55. Molecules implicated in reverse 
signalling by A-ephrins include the Src family kinases Lck and Fyn, and PI3K52. 
A Mechanistic Model for γδ T Cell recognition of EphA2 
The aforementioned considerations suggest a model whereby EphA2 binds to the ephrins on 
the surface of the T cell, which promotes the formation of a complex with the MAU TCR, 
possibly complementing a weak TCR interaction with EphA2. This clustering would then initiate 
a phosphorylation cascade of signalling molecules, leading to T cell activation. The significant 
role of Lck in TCR signalling potentially suggests a system in which the ephrins fulfil the role of 
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the co-receptors CD4 and CD8 in αβ T cell recognition in localising Lck to the site of the TCR, to 
phosphorylate CD3ζ. This system would combine the natural specificity of the ephrins for a 
surface molecule known to play a major role in transformation of some cancers, with the ability 
of the γδ TCR to initiate T cell signalling and downstream effector responses7. 
The suggested model postulates that γδ T cells, such as MAU, may have a tumour surveillance 
role, using A-ephrins as an ‘invariable receptor’ in combination with the γδ TCR to quickly 
identify an epithelia assocated stress antigen, EphA2. Increased understanding of the molecular 
nature of this interaction may open up the possibilty of identifying other Vδ1+ T cells capable of 
recognising EphA2 or conceivably other related epithelia-associated stress ligands. Ultimately, 
increased understanding in this area will hopefully advance the field of γδ in immunobiology, 
and potentially facilitate the manipulation of γδ T cells in cancer immunotherapy. 
17 
Materials and Methods 
Generation of JRT3-MAU and Cell Cultures 
cDNA encoding the Vγ and Vδ chains of the MAU (Vγ9 Vδ1) T cell clone was transduced into 
JRT3.5 cells (ATCC) via  a lentiviral vector (Carried out by Willcox et al., unpublished). JRT3-MAU 
and HT29 cells were maintained in RPMI and DMEM media respectively, containing 8% HI-FCS 
(Sigma).  
Signalling Activation Assays 
24 well plates (Iwaki) were coated overnight at 4°C with the following: OKT3 (10μg/ml) and 
EphA2-Fc (20μg/ml). JRT3-MAU was serum starved by washing in serum-free RPMI (sfRPMI), 
and culture in sfRPMI overnight. 
2x106 of pre-warmed JRT3-Mau cells (in 200μl pre-warmed sfRPMI) are added to each well and 
incubated at 37°C for the following time points: 0, 2, 5, 20 and 30 minutes. Samples were 
transferred to a pre-chilled eppendorf on ice, and the well washed vigorously with chilled PBS 
twice and transferred to the eppendorf to ensure all cells are transferred. 
Cells were washed twice in chilled PBS and lysed in 100ul of 2.5X SDS Loading Buffer (+0.4M 
DTT) lacking bromophenol blue with 1x Protease and Phosphatase Inhibitor (PPI) Cocktail 
(Pierce). Lysates were then boiled (95°C/ 10 minutes) with intermittent vortexing and then 
frozen. Samples were subjected to repeated freeze thaw cycles until they were no longer 
viscous, to allow for accurate measuring. 
In order to quantify the protein concentration of each sample, they were diluted 1:10 in 
distilled water and subjected to the colourimetric Biorad DC protein assay in a flat bottomed 96 
well plate. 
Finally, 1μl of 5X SDS loading buffer containing bromophenol blue was added to visualisation of 
the sample on the gel and boiled for 10 minutes at 95°C with intermittent vortexing. 
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SDS PAGE and Western Blots 
The results from the protein quantification assay were used to calculate the volume of each 
sample to be loaded into polyacrylamide gels to ensure that the total volume of protein loaded 
was equal. Samples were normalised so that 5-10µg of total protein was loaded into each well. 
Samples were boiled (95°C/10 minutes) and pulsed in the micro-centrifuge for 1 minute before 
being loaded into the gels. SDS-PAGE was then carried out, and the separated gels were then 
transferred to PVDF membrane (GE Healthcare) and blocked with 3% BSA .  
The membranes were then treated with either of  the following primay antibodes: mouse 
antiphospho CD3ζ (EBioscience) goat anti-phopho Zap70 (T-cell signalling) and anti βactin 
(origin unknown) and incubated for 1h at RT on a shaker. After washing membranes with TBS + 
0.1% Tween-20, secondary antibodies were applied, diluted in 5% milk solution: rabbit anti 
mouse HRP and goat anti rabbit HRP. 
The blots were then treated with EZ-ECL (Biological Industries) for 5 minutes, and developed at 
various exposures.  
Densitometry 
In order to semi-quantitate the western blot bands obtained, densitometry was used. A 
detailed protocol of the procedure was procured from56. Briefly, digitized 8-bit scans of the 
developed film were obtained. ImageJ software was then used to determine the relative 
density of dark pixels of the desired bands in each lane compared to the 0 time point control. 
FACS activation 
Flat bottomed 96 well plates (Iwaki) were incubated with either of the following antibodies: 
OKT3 (Millipore), EphA2-Fc, EphA4-Fc (R&D) and anti-γδ, in 100μl PBS at 10μg/ml, overnight at 
4°C. Adherent HT29 cells in DMEM media were also coated onto the wells overnight at 37°C. 
Wells were washed out twice with PBS, and 1x105 JRT3-Mau (in 100μl) were added and 
incubated at 37°C for the appropriate time (CD3 downregulation, 0, 15, 30, 45, 60 and 120 
minutes, and for CD69 upregulation, 0, 1, 2, 3 and 4h). At each time point, samples were 
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removed and placed in a pre-chilled 96 well round bottom plate on ice. Wells were washed 
twice with PBS to remove any residual cells, and transferred to the chilled plate. 
Cells were stained in a round bottom 96 well plate by the following antibodies: anti CD69-PeCy5 
(BD), anti CD3-FITC (BD) for 30min on ice in 2%FCS-PBS. Cells were then washed and fixed with 
1% paraformalydehyde. Samples were stored at 4°C until analysed by flow cytometry (BD LSR II) 
PI-PLC Treatment 
0.8 units of PI-PLC (Sigma) was added to 1x106 JRT3-Mau cells, and incubated for 45 minutes at 
37°C. After the incubation the cells were washed and resuspended in the original conditioned 
media (i.e. the supernatant after spinning down the cells). This was to reduce any stimulus 
caused by adding fresh media and serum during the 1h incubation, overcompensating for any 
reduction in ephrin signalling. 
Wells were coated overnight as previously described with the following antibodies, OKT3, 
EphA2-Fc, EphA4-Fc and anti-γδ. PI-PLC, and non-treated cells were added to the wells and 
incubated for 1h at 37°C  
As well as being stained with anti CD69-PeCy5, PI-PLC and non-treated controls were stained 
with EphA4-Fc , EphA2-Fc and EphrinA1-Fc (and subsequently with goat anti-human AF488 
(Invitrogen)) to measure the level of ephrin cleavage also. 
Blocking experiments 
Blocking of the plate bound EphA2-Fc was achieved by incubating with either 6G8 or ephrinA1-
Fc (both at 10μg/ml) for 105 minutes. Wells were then washed and incubated for 4 hours with 
1x105 JRT3-MAU as detailed previously, and CD69 expression was determined by flow 
cytometry with an anti CD69-PeCy5 antibody. 
Blocking of the ephrins on the cell surface of JRT3-Mau was achieved by incubating JRT3-Mau 
with EphA4-Fc (20μg/ml) and incubated for 30 minutes on ice. Cells were then washed, 
resuspended in conditioned media and added to the plate as previously described. 
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Results 
JRT3-Mau is Activated by EphA2 
In order to independently confirm that plate bound EphA2-Fc is capable of activating JRT3 Mau, 
JRT3-MAU was incubated with plate bound EphA2-Fc for up to 4h. Activation was measured bt 
CD69 upregulation, an early activation marker. Over time, the surface expression of CD69 is 
significantly upregulated on JRT3-MAU after activation, in a similar fashion and timescale as 
when activated by the activating OKT3 anti CD3ε antibody (Figure 3). CD69 levels continue to 
rise over the 4h time course, but are significant by 1 hour. There is no significant upregulation 
of CD69 by plate bound EphA4-Fc, which binds the same ephrins as EphA2, indicating that CD69 
upregulation by EphA2 is not a nonspecific effect of cross-linking ephrin receptors on JRT3-
MAU.. 
 
 
Figure 3: Confirmation that plate bound EphA2 activates JRT3 Mau 
JRT3-MAU cells were incubated with either plate bound EphA2-Fc, EphA4-Fc or OKT3 for up to 4h. Activation status 
was measured at various time points by CD69 expression levels. 
These results therefore confirm that the ephrin receptor EphA2 is capable of activating JRT3-
MAU when plate bound. 
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Activation of JRT3-MAU by EphA2-Fc Results in Phosphorylation of TCR Signalling 
Components 
Despite showing that transfection of the MAU TCR into JRT3 cells confers reactivity to EphA2, 
the failure to demonstrate direct TCR:EphA2 binding by SPR could mean that the transfection 
protocol has altered other pathways in the JRT3 cells, giving the impression of a TCR dependent 
reaction with EphA2. Therefore, in order to explore whether the TCR is actually involved in 
JRT3-MAU activation by EphA2, the phosphorylation status of important signalling components 
of the T cell signalling cascade was determined following activation by EphA2.  
 
Figure 4: Phosphorylation of TCR Signalling Components following EphA2 activation 
JRT3 Mau cells were incubated with either plate bound EphA2-FC or OKT3 for up to 30 minutes.(A) 
Representative western blots stained with either anti pCD3z or pZap70, with Actin as a loading control. (B) 
Representative fold increase of phosphorylation of CD3z and Zap70s relative to the zero time point, as 
measured by densitometry. 
CD3ζ and Zap70 were strongly phosphorylated following OKT3 stimulation, with peak intensity 
between 2 and 5 minutes post activation (Figure 4A). Similarly, CD3ζ and Zap70 were also 
phosphorylated following activation by EphA2, but to a lesser degree.  
Figure 4B shows fold changes in phosphorylation levels relative to the zero time point. All sets 
show an increase in phosphorylation status of CD3z and Zap70 at 2-5 minutes, after which they 
begin to decline back to basal levels. This pattern is similar to what is conserved in conventional 
αβ and γδ signalling52, and the OKT3 controls. Thus suggesting that the Mau TCR is involved in 
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an active manner in activation of JRT3-Mau by EphA2, resulting in phosphorylation of 
conventional downstream signalling components. 
Activation by EphA2 & HT29 Result in TCR Downregulation from the Cell Surface 
A result of TCR activation in conventional αβ T cells is the downregulation of the TCR from the 
cell surface following activation. This process regulates the T cell response, preventing 
potentially damaging constitutive responses from cells, and has also been observed in γδ T cell 
signalling 57 
 
Figure 5: CD3 is down regulated on JRT3 MAU following activation by EphA2 and HT29 
JRT3 Mau cells were incubated in the presence of OKT3, EphA4-Fc, EphA2-FC or a monolayer of HT29 cells. CD3 
levels were measured at various time points via flow cytometry. 
Following activation by plate bound OKT3, TCR:CD3 complexes are strongly down regulated, 
reaching maximal downregulation by 45 minutes (Figure 5). No downregulation is observed for 
EphA4. As expected downregulation is not as complete for EphA2 as for OKT3 cross linking, but 
occurs in the same timeframe, with maximal downregulation within an hour. This moderate 
downregulation is consistent with weak affinity interactions, as expected by the weak bending 
affinity predicted by the lack of SPR data 58. 
JRT3-Mau cells were also incubated with HT29 cells, a human colon adenocarcinoma cell line 
which expresses EphA2 and activates JRT3-MAU. Incubation of JRT3-MAU with these cells down 
regulated CD3 in a similar fashion to EphA2, supporting the result in a more physiologically 
relevant system which should allow the involvement of co-receptors and co-stimulatory ligands, 
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hence reducing the likelihood of the result being an artefact of an artificial plate bound system. 
Although the TCR downregulation observed was modest, it was observed to occur follwing 
activation with both EphA2-Fc and HT29 cells, and further indicates that the TCR is involved in 
JRT3-MAU activation by EphA2. 
Activation can be Inhibited by Blocking with Soluble Ephrin A1 
The data previously presented in this report has indicated that EphA2 is stimulating JRT3-Mau 
via the TCR. Since the affinity of MAU-TCR:EphA2 binding is below the strength detectable by 
SPR, there could potentially be other co-receptors expressed by JRT3-MAU which are involved 
in activation. As discussed already, the ephrins are the best candidates for this role, as they are 
the natural EphA2 ligands. Ephrins have been shown to be expressed on CD4+ T cells, but 
expression on γδ T cells has not been described. To address weather ephrins are expressed on 
JRT3-MAU cells, the cells were stained with either EphA2-Fc or ephrinA1-Fc, a control Fc 
protein, and staining of EphA2-Fc was observed by flow cytometry (Figure 6). 
 
Figure 6: JRT3 Mau Cells Express Ephrins on the Cell Surface, and are cleaved by PI -PLC 
(A) JRT3 Mau cells were stained with EphA2-Fc and an anti-human Fc AF700 and analysed by flow 
cytometry. The control is the sample stained with anti-human Fc AF488 antibody alone. (B) Treatment 
of JRT3 Mau cells with PI-PLC prevents staining by EphA2-Fc, showing that all A-Ephrins are removed 
from the cell surface. 
If the binding of ephrins on the T cell surface to EphA2 is important for activation, then the 
blocking of the ephrin ligand binding domain (LBD) on EphA2 by ephrin A1-Fc should prevent 
activation of JRT3 Mau.  
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Figure 7: Blocking the EphA2 LBD blocks JRT3 MAU activation 
Plate bound EphA2-Fc was pre-blocked with ephrinA1-Fc for 30 minutes at room temperature before incubation 
with JRT3 Mau cells for 4 hours. Surface levels of CD69 were measured by flow cytometry. 
Blocking the EphA2 LBD with ephrin A1-Fc decreased the activation of JRT3-MAU by EphA2-Fc 
(Figure 7).  
Also it would be useful to repeat the experiment using a non Fc bound ephrin-A1 construct. The 
important activatory domain of EphA2 may be distinct site to the ephrin LBD, but the large Fc 
construct of an ephrin-Fc bound elsewhere may be sterically hindering interactions at this 
region of the protein. 
JRT3 Mau Surface Ephrins are Required for Mau Mediated Signalling 
In order to assess whether the ephrins on the surface of JRT3-Mau are important in activation, 
they were pre blocked with EphA4-Fc to prevent the binding of ephrins to the plate bound 
EphA2-Fc.  
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Figure 8: Blocking of JRT3 surface ephrins with sEPhA4-Fc 
JRT3 Mau cells were pre-blocked with EphA4-Fc before incubation with plate bound EphA2-Fc. Surface levels of 
CD69 were measured by flow cytometry. 
Treatment with sEphA4-Fc did not inhibit activation by EphA2-Fc (Figure 8). This could be 
because during the 1 hour incubation at 37°C, the ephrins are likely to be internalised from the 
cell surface, along with the bound EphA4-Fc. This was thought to be minimised by incubating 
the assay for only 1 h, after which CD69 upregulation is noticeable but no maximal (Figure 3), 
but it is likely still long enough for ephrin recycling to occur. It would therefore be useful to 
stain the surface of Mau for the presence of the sEphA4-Fc construct using anti human Fc 
antibodies by flow cytometry, to determine if levels of EphA4-Fc change significantly over the 
course of the incubation. 
Another method of addressing the importance of ephrins on the surface of JRT3-MAU surface is 
to remove them completely. EphA2 binds only A-type ephrins, which are tethered to the cell 
surface by GPI linkages. These ephrins were removed by treatment with PI-PLC, an enzyme 
which cleaves GPI linkages.  
26 
 
Figure 9: PI-PLC Treatment prevents JR3 Mau Activation by EphA2-Fc 
JRT3 Mau cells were treated with PI-PLC for 45 minutes to remove GPI linked surface proteins, and then incubated 
for 1h with plate bound EphA2-Fc. Surface levels of CD69 were determined by flow cytometry. 
After treatment with PI-PLC, EphA2 fails to upregulate CD69 on the surface of JRT3 Mau (Figure 
9). Cleavage of ephrins was shown to be complete by the lack of EphA2-Fc binding following PI-
PLC treatment, as detected by fluorescent anti human Ig antibodies [Figure 6B]. 
PI-PLC treatment is a particularly harsh, nonspecific approach as it indiscriminately cleaves all 
GPI linked proteins, of which there are many on the cell surface, performing a wide variety of 
functions. PI-PLC treated cells were still activated by OKT3 and an activatory anti-γδ Ab, which 
shows that the cell is still capable of signalling after treatment, and the inhibition of EphA2 
mediated signalling is not due to non-specific inhibitory consequences of PI-PLC treatment. 
These experiments show that the presence of GPI anchored proteins, of which A-type ephrins 
are an example, are essential for the activation of Mau by plate bound EphA2, as their complete 
removal completely inhibits activation. A more specific approach would be ideal to complement 
these experiments, specifically the use of ephrin specific antibodies to block ephrin recognition 
by EphA2, which would narrow down the cause of the lack of activation to particular ephrins. 
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Discussion 
The ‘lymphoid stress surveillance’ hypothesis proposes a role for unconventional T cell subsets 
in the detection and control of both pathologically and stress induced epithelial damage7. Vδ1+ 
γδ T cells have been shown to play a key role in epithelial lymphoid stress surveillance, but the 
molecular mechanism of their detection of stress antigens via their TCR is lacking. This study 
has built upon this framework by firstly confirming that a particular Vδ1+ γδ T cell clone, MAU, 
can be activated by an epithelial stress ligand EphA2, in a TCR dependant manner, and then 
directly addressing the molecular mechanisms underlying this interaction. 
This investigation aimed to explore the molecular mechanisms of the interaction between 
EphA2 and the MAU T cell. Ephrins were postulated to be central to the activation of JRT3-MAU 
by EphA2 because SPR analysis could not detect binding between MAU TCR and EphA2; 
suggesting a weak interaction which is dependent on T cell surface ephrins. 
In summary, the data firstly confirm that isolated EphA2 is able to activate JRT3-MAU in a TCR 
dependent manner. Secondly, they have established that activation results in receptor 
downregulation as well as the phosphorylation of key proximal TCR signalling molecules such as 
ZAP70 and CD3ζ. Finally the data suggest that the ephrins on the T cell surface are essential for 
MAU activation by EphA2. Collectively these data suggest a novel mechanism of T cell 
activation, possibly involving the formation of a complex between the MAU γδ TCR and ephrins 
on the T cell surface. 
EphA2 Activates MAU in a TCR Dependent Manner 
Previous studies indicated that the MAU clone was able to recognise target cells in a TCR 
dependant manner based on recognition of EphA2. Conceivably this mode of recognition could 
reflect a Vδ1 contribution to epithelial stress surveillance of dysregulated EphA2 on 
transformed or infected epithelial cells as part of the lymphoid stress surveillance response. 
JRT3-MAU was incubated with a plate bound EphA2-FC construct and CD69 upregulation, an 
early activation marker to T cells, was detected on the surface of JRT3-MAU. Importantly, this 
confirms that EphA2 in isolation is sufficient to activate JRT3-MAU. 
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It would be useful to complement the detection of this early activation marker with assays to 
determine whether the CD69HIGH MAU cells are functionally active. Such assays could include an 
intracellular cytokine stain, whereby activated cells are screened for the production of pro-
proliferate cytokines, such as IL2, or markers of T cell effector function, such and the 
granulation marker CD107. Effector functions of the activated MAU cells could also be 
determined by cell killing assays, whereby the ability of activated MAU to kill EphA2 expressing 
cancer lines could be determined.  
A key aim of this investigation was to determine the significance of the MAU γδ TCR in the 
activation of MAU by EphA2, but CD69 upregulation is not exclusive to TCR mediated activation, 
and may also be induced by other activatory stimuli, such as anti CD2 mAbs, activators of 
protein kinase C and phytohemagglutinins (PHA) (Reviewed in 59). Therefore, in order to 
exclude the possibility that the CD69 upregulation detected is a result of a non-TCR mediated 
interaction between EphA2 and another molecule on the surface of JRT3 MAU, direct 
involvement of the TCR in the activation needs to be shown. 
The phosphorylation of key signalling components of the T cell signalling cascade, particularly 
CD3ζ and ZAP70, are among the earliest events in TCR mediated activation of lymphocytes. 
Therefore the observed increased phosphorylation of these key proteins following JRT3-MAU 
activation by EphA2 strongly suggests that the TCR is indeed involved in the activation. 
In terms of the experiments conducted, an omission is the lack of a negative control; the use of 
which would exclude the possibility that the observed effects are non-specific. EphA4 would 
serve as an ideal control, as it is able to bind the same ephrins as EphA2, but has been ben 
demonstrated to activate JRT3-MAU. 
The experimental design could also be optimised by altering the method by which 
phosphorylation status is quantified. The current process of digitising the images and 
performing densitometry adds a relatively large potential for errors and subjectivity, which is 
well documented60. Briefly, the main difficulty is in determining a suitable background level, 
which can vary due to a myriad of factors both within individual blots and across the groups of 
experiments60. To reduce these inherent errors, a system such as the LiCore Odyssey infrared 
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imaging system could be used, which directly detects up to two membrane bound antibodies 
conjugated to an IR emitting fluorochrome. This system is capable of detecting two different 
bound antibodies on the same western blot, and combined with the lack of requirement to 
develop photographic film will make it possible to make direct comparisons of absolute 
phosphorylation levels between samples. This process has been used successfully by other 
groups in detecting ZAP70 phosphorylation61. 
Another key indication of TCR mediated activation is the downregulation of TCR from the T cell 
surface immediately following activation. Following incubation of JRT3-MAU cells with either 
plate bound EphA2-FC or a HT29 monolayer, a modest TCR down regulation was observed. The 
consistency between these two experimental approaches is promising, indicating that the down 
regulation, however modest, is consistent between two different experimental approaches, 
supporting that it is a genuine observation. Previous studies have shown that αβ T cells 
expressing TCRs with low affinity for specific pMHC complexes show similarly low levels of TCR 
downregulation post activation, while a significant amount of specific killing is still detected58,62. 
These studies support our data, as the lack of binding between MAU TCR and EpHA2 detected 
by SPR suggests a weak interaction, and so TCR down regulation would be expected to be 
modest. They also indicate that despite relatively low TCR downregulation, low affinity 
pMHC/αβ TCR interactions are still able to elicit significant effector functions. 
Collectively, these data suggest that the MAU TCR is both required and actively involved in the 
activation of JRT3-MAU by EphA2. This complements the findings by Halary et al. in 2005 that 
the recognition of CMV infected and transformed cells by the MAU clone is TCR dependent, as 
detected by TCR downregulation and mAb TCR blocking assays11. 
Ephrins on the T Cell Surface Play a Key Role in Activation by EphA2 
Thus far, the data collected in this project have shown that EphA2 activates JRT3-MAU in a TCR 
dependent manner. The project also aimed to determine the molecular nature of this 
previously uncharacterised interaction. The suspected low affinity interaction between MAU 
TCR and EphA2 lead us to postulate the involvement of additional molecules in the activation 
process, specifically the A-ephrins, the cognate ligands for EphA2, on the surface of MAU. In 
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addition, GPI linked A-ephrins have been shown to have the capacity to propagate signals in the 
cells they are expressed on, as a result of complexing with proteins possessing a cytosolic 
region with signalling potential54.  
The ligand binding domain (LBD) of EphA2 appeared to be required for activation, as blocking of 
the LBD with an ephrinA1-Fc construct reduced the amount of CD69 upregulation detected 
compared to the upregulation detected in untreated control samples. The experimental 
approach could be refined however, as the presence of the human FC region on the ephrin-A1 
construct does not make the assay specific enough. Conceivably, steric effects could be caused 
by the Fc region, such as blocking interactions at sites distinct from the LBD that are involved in 
activation. Use of an ephrin-A1 construct lacking the Fc moiety could exclude this possibility, 
and would substantiate the role of the EphA2 LBD in activation. 
The suggestion that the LBD of EphA2 is required for activation of JRT3-MAU by EphA2 supports 
the role of ephrins in the interaction. In order to clarify the importance of ephrins on the T cell 
surface, experiments whereby the JRT3-MAU surface ephrins were pre-blocked with an EphA4-
Fc construct prior to incubation with EphA2-Fc showed no inhibition of the activatory capacity 
of EphA2 on JRT3-MAU. These experiments are inconclusive and should be repeated with 
several considerations in mind. Ephrins are actively involved in signalling processes, and are 
likely to be down-regulated from the cell surface following binding63, leading to removal of 
blocked ephrins from the cell surface, and their replacement with de novo unbound 
counterparts. A more robust way to test the importance of A-ephrins on the surface of JRT3-
MAU was to treat cells with PI-PLC, an enzyme which non-discriminately cleaves GPI-linked 
proteins from the cell surface. PI-PLC treated, A-ephrinnegative cells were not activatable by plate-
bound EphA2, whereas their ability to be activated by both anti γδ and anti CD3 mAbs was 
unaffected. This therefore suggests that JRT3 surface ephrins are required for the activation of 
JRT3-MAU by EphA2. 
The suggested importance of A-ephrins in JRT3-MAU activation by EphA2 is supported by 
previous studies, in which reverse signalling via A-ephrins has been shown to be able to activate 
Lck, a key kinase in the initiation of the αβ TCR signalling cascade52. This therefore suggests a 
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role for ephrins to recruit Lck to the EphA2/MAU TCR complex, which then could initiate the 
earliest stages of TCR mediated signalling, specifically CD3ζ phosphorylation. 
Future Directions 
In order to expand upon the findings of this investigation and explore the new potential ideas it 
exposes, more research into the nature of the interaction of MAU TCR with EphA2 is needed. In 
addition to the improvements to the experimental designs already mentioned, different 
approaches could also be used. 
In order to expand upon the idea that MAU TCR, A-ephrins and EphA2 localise together and 
form a signalling complex, several approaches could be used. Firstly, immunofluorescence 
based approaches such as Fluorescence Resonance Energy Transfer (FRET) analysis could be 
used to visualise the location of the different components during both activatory and non 
activatory conditions. To supplement these localisation experiments, a co-immunoprecipitation 
(Co-IP) could be conducted in order to detect any potential interactions between the 
molecules. This approach could also be used to identify any further molecules which may be 
complexing with EphA2/MAU TCR; as the precipitated complex could be analysed by mass 
spectrometry. 
In order to expand these findings beyond the artificial Jurkat system for increased biological 
relevance, the first step would be to analyse ex vivo Vδ1+ γδ T cells for ephrin expression, and 
how they change in response to common signals of infection, such as TNFα and IFNγ. 
Concluding Remarks 
This investigation has supplemented previous work suggesting that EphA2 can activate JRT3-
MAU cells via its γδ TCR. We have also shown that ephrins on the surface of the JRT3 cell are 
essential for full activation or JRT3-MAU by EphA2.  
The lymphoid stress surveillance hypothesis proposes a role for epithelium resident Vδ1+ γδ T 
cells in the detection and control of both infection and stress mediated damage. This suggests 
that EphA2, an antigen heavily unregulated on epithelial cells in response to stress, is capable of 
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activating the Vδ1+ JRT3-MAU T cell via its γδ TCR. This activation was found to also be 
dependent on JRT3 surface A-ephrins; a finding which begins to deconstruct the molecular 
mechanism of this interaction.  
This increased understanding will not only form the basis of further research into this specific 
ligand/receptor interaction, but will hopefully also aid the discovery and characterisation of 
further Vδ1+ γδ TCR interactions with other epithelial stress related ligands, exposing potential 
new targets for therapeutic approaches. 
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Appendix 
Appendix Figure 1: Identification of 6G8 ligand 
(A) Graph showing the TCR specific blocking of JRT3 Mau activation by 6G8 with the activatory U373 cell line. (B) Silver nitrate 
stain showing the identification of a 130Kda band in MAU activatory cell lines following immunoprecipitation with 6G8. 
Original Mau Blocking
0
O
K
T3
m
E
ph
A
2-
Fc
 P
la
te
bo
un
d
U
37
3
U
37
3 
+ 
M
au
 6
G
8
U
37
3 
+ 
Ig
G 0
O
K
T3
m
E
ph
A
2-
Fc
 P
la
te
bo
un
d
U
37
3
U
37
3 
+ 
M
au
 6
G
8
U
37
3 
+ 
Ig
G
0
2000
4000
6000
JRT3 LES
JRT3 MAU
C
D
6
9
-P
E
 M
F
I
A B 
34 
References 
1. Ryan, G. T cell signalling: CD3 conformation is crucial for signalling. Nat Rev Immunol 10, 
7-7 (2010). 
2. Hedrick, S.M., Cohen, D.I., Nielsen, E.A. & Davis, M.M. Isolation of cDNA clones encoding 
T cell-specific membrane-associated proteins. Nature 308, 149-53 (1984). 
3. Hein, W.R. & Dudler, L. Divergent evolution of T cell repertoires: extensive diversity and 
developmentally regulated expression of the sheep gamma delta T cell receptor. EMBO J 
12, 715-24 (1993). 
4. Hayday, A.C. γδ Cells: A Right Time and a Right Place for a Conserved Third Way of 
Protection. Annual review of immunology 18, 975-1026 (2000). 
5. Medzhitov, R. & Janeway, C., Jr. Innate immune recognition: mechanisms and pathways. 
Immunol Rev 173, 89-97 (2000). 
6. Rock, K.L. & Kono, H. The inflammatory response to cell death. Annu Rev Pathol 3, 99-
126 (2008). 
7. Hayday, A.C. Gammadelta T cells and the lymphoid stress-surveillance response. 
Immunity 31, 184-96 (2009). 
8. Groh, V., Steinle, A., Bauer, S. & Spies, T. Recognition of stress-induced MHC molecules 
by intestinal epithelial gammadelta T cells. Science 279, 1737-40 (1998). 
9. Tigelaar, R.E., Lewis, J.M. & Bergstresser, P.R. TCR gamma/delta+ dendritic epidermal T 
cells as constituents of skin-associated lymphoid tissue. J Invest Dermatol 94, 58S-63S 
(1990). 
10. Strid, J., Tigelaar, R.E. & Hayday, A.C. Skin immune surveillance by T cells--a new order? 
Seminars in immunology 21, 110-20 (2009). 
11. Halary, F. et al. Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against 
cytomegalovirus-infected cells and tumor intestinal epithelial cells. The Journal of 
experimental medicine 201, 1567-78 (2005). 
12. Tanaka, Y. et al. Natural and synthetic non-peptide antigens recognized by human 
[gamma][delta] T cells. Nature 375, 155-158 (1995). 
13. Goldstein, J.L. & Brown, M.S. Regulation of the mevalonate pathway. Nature 343, 425-
30 (1990). 
14. Altincicek, B. et al. Cutting edge: human gamma delta T cells are activated by 
intermediates of the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid 
biosynthesis. J Immunol 166, 3655-8 (2001). 
15. Fisch, P. et al. Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on 
Daudi Burkitt's lymphoma cells. Science 250, 1269-73 (1990). 
16. De Libero, G. et al. Selection by two powerful antigens may account for the presence of 
the major population of human peripheral gamma/delta T cells. J Exp Med 173, 1311-22 
(1991). 
17. Gober, H.-J. et al. Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate 
Metabolites in Tumor Cells. The Journal of experimental medicine 197, 163-168 (2003). 
35 
18. Scotet, E. et al. Tumor recognition following Vgamma9Vdelta2 T cell receptor 
interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. 
Immunity 22, 71-80 (2005). 
19. Vantourout, P. et al. Specific requirements for Vgamma9Vdelta2 T cell stimulation by a 
natural adenylated phosphoantigen. J Immunol 183, 3848-57 (2009). 
20. Rajasekar, R., Sim, G.K. & Augustin, A. Self heat shock and gamma delta T-cell reactivity. 
Proc Natl Acad Sci U S A 87, 1767-71 (1990). 
21. Sciammas, R. & Bluestone, J.A. HSV-1 glycoprotein I-reactive TCR gamma delta cells 
directly recognize the peptide backbone in a conformationally dependent manner. J 
Immunol 161, 5187-92 (1998). 
22. Hayday, A., Theodoridis, E., Ramsburg, E. & Shires, J. Intraepithelial lymphocytes: 
exploring the Third Way in immunology. Nat Immunol 2, 997-1003 (2001). 
23. Spada, F.M. et al. Self-recognition of CD1 by gamma/delta T cells: implications for innate 
immunity. J Exp Med 191, 937-48 (2000). 
24. Groh, V. et al. Broad tumor-associated expression and recognition by tumor-derived 
gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 96, 6879-84 (1999). 
25. Diefenbach, A. & Raulet, D.H. The innate immune response to tumors and its role in the 
induction of T-cell immunity. Immunol Rev 188, 9-21 (2002). 
26. Jones, B. et al. Molecular analysis of T cell receptor gamma gene expression in allo-
activated splenic T cells of adult mice. European Journal of Immunology 18, 1907-1915 
(1988). 
27. Allison, T.J., Winter, C.C., Fournie, J.J., Bonneville, M. & Garboczi, D.N. Structure of a 
human gammadelta T-cell antigen receptor. Nature 411, 820-4 (2001). 
28. Thedrez, A. et al. Self/non-self discrimination by human gammadelta T cells: simple 
solutions for a complex issue? Immunol Rev 215, 123-35 (2007). 
29. Tanaka, Y. Human gamma delta T cells and tumor immunotherapy. J Clin Exp Hematop 
46, 11-23 (2006). 
30. Girardi, M. et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 
294, 605-9 (2001). 
31. Matsuda, S., Kudoh, S. & Katayama, S. Enhanced formation of azoxymethane-induced 
colorectal adenocarcinoma in gammadelta T lymphocyte-deficient mice. Jpn J Cancer 
Res 92, 880-5 (2001). 
32. Ma, Y. et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of 
anticancer chemotherapy. J Exp Med 208, 491-503 (2011). 
33. Meraviglia, S. et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate 
and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin 
Exp Immunol 161, 290-7 (2010). 
34. Dieli, F. et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 
for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67, 7450-7 
(2007). 
35. Wilhelm, M. et al. Gammadelta T cells for immune therapy of patients with lymphoid 
malignancies. Blood 102, 200-6 (2003). 
36. Couzi, L. et al. Cytomegalovirus-induced gammadelta T cells associate with reduced 
cancer risk after kidney transplantation. J Am Soc Nephrol 21, 181-8 (2010). 
36 
37. Couzi, L. et al. Common features of gammadelta T cells and CD8(+) alphabeta T cells 
responding to human cytomegalovirus infection in kidney transplant recipients. J Infect 
Dis 200, 1415-24 (2009). 
38. Sinzger, C. et al. Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells 
are major targets of human cytomegalovirus infection in lung and gastrointestinal 
tissues. J Gen Virol 76 ( Pt 4), 741-50 (1995). 
39. Scheffer, G.L. et al. Expression of the vascular endothelial cell protein C receptor in 
epithelial tumour cells. Eur J Cancer 38, 1535-42 (2002). 
40. Wykosky, J. & Debinski, W. The EphA2 receptor and ephrinA1 ligand in solid tumors: 
function and therapeutic targeting. Molecular cancer research : MCR 6, 1795-806 
(2008). 
41. Pasquale, E.B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. 
Nature reviews. Cancer 10, 165-80 (2010). 
42. Pasquale, E.B. Eph-ephrin promiscuity is now crystal clear. Nat Neurosci 7, 417-8 (2004). 
43. Coffman, K.T. et al. Differential EphA2 Epitope Display on Normal versus Malignant Cells. 
Cancer Res. 63, 7907-7912 (2003). 
44. Lindberg, R.A. & Hunter, T. cDNA cloning and characterization of eck, an epithelial cell 
receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell Biol 
10, 6316-24 (1990). 
45. Walker-Daniels, J., Hess, A.R., Hendrix, M.J. & Kinch, M.S. Differential regulation of 
EphA2 in normal and malignant cells. Am J Pathol 162, 1037-42 (2003). 
46. Surawska, H., Ma, P.C. & Salgia, R. The role of ephrins and Eph receptors in cancer. 
Cytokine & growth factor reviews 15, 419-33 (2004). 
47. Zantek, N.D. et al. E-cadherin regulates the function of the EphA2 receptor tyrosine 
kinase. Cell Growth Differ 10, 629-38 (1999). 
48. Zelinski, D.P., Zantek, N.D., Stewart, J.C., Irizarry, A.R. & Kinch, M.S. EphA2 
overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61, 2301-
6 (2001). 
49. Wykosky, J., Gibo, D.M. & Debinski, W. A novel, potent, and specific ephrinA1-based 
cytotoxin against EphA2 receptor expressing tumor cells. Mol Cancer Ther 6, 3208-18 
(2007). 
50. Carles-Kinch, K., Kilpatrick, K.E., Stewart, J.C. & Kinch, M.S. Antibody targeting of the 
EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 62, 2840-7 (2002). 
51. Doyle, C. & Strominger, J.L. Interaction between CD4 and class II MHC molecules 
mediates cell adhesion. Nature 330, 256-9 (1987). 
52. Holen, H.L. et al. Signaling through ephrin-A ligand leads to activation of Src-family 
kinases, Akt phosphorylation, and inhibition of antigen receptor-induced apoptosis. 
Journal of leukocyte biology 84, 1183-91 (2008). 
53. Irie, N. et al. Bidirectional signaling through ephrinA2-EphA2 enhances 
osteoclastogenesis and suppresses osteoblastogenesis. J Biol Chem 284, 14637-44 
(2009). 
54. Davy, A. et al. Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn 
tyrosine kinase to regulate cellular adhesion. Genes & Development 13, 3125-3135 
(1999). 
37 
55. Davy, A. & Robbins, S.M. Ephrin-A5 modulates cell adhesion and morphology in an 
integrin-dependent manner. The EMBO journal 19, 5396-405 (2000). 
56. Miller, L. Analyzing gels and western blots with ImageJ Vol. 2010 (2010). 
57. Valitutti, S. Degradation of T Cell Receptor (TCR)-CD3-zeta Complexes after Antigenic 
Stimulation. Journal of Experimental Medicine 185, 1859-1864 (1997). 
58. Derby, M.a., Wang, J., Margulies, D.H. & Berzofsky, J.a. Two intermediate-avidity 
cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC 
tetramer staining. International immunology 13, 817-24 (2001). 
59. Castellanos, M.C. et al. Expression of the leukocyte early activation antigen CD69 is 
regulated by the transcription factor AP-1. J Immunol 159, 5463-73 (1997). 
60. Gassmann, M., Grenacher, B., Rohde, B. & Vogel, J. Quantifying Western blots: pitfalls of 
densitometry. Electrophoresis 30, 1845-55 (2009). 
61. Salmond, R.J., Filby, A., Pirinen, N., Magee, A.I. & Zamoyska, R. Mislocalization of Lck 
impairs thymocyte differentiation and can promote development of thymomas. Blood 
117, 108-17 (2011). 
62. Valitutti, S., Muller, S., Dessing, M. & Lanzavecchia, A. Different responses are elicited in 
cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 183, 
1917-21 (1996). 
63. Pitulescu, M.E. & Adams, R.H. Eph/ephrin molecules--a hub for signaling and 
endocytosis. Genes Dev 24, 2480-92 (2010). 
 
 
  
38 
PROJECT 2 
Investigation into the Chemokine Profile of Ag-
Specific T Cell Responses in Multiple Myeloma and 
MGUS Patients Compared To Age-Matched 
Controls 
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Introduction 
Multiple Myeloma 
Multiple Myeloma (MM) is a haemopoietic malignancy which is characterised by the 
accumulation of a monoclonal population of malignant plasma cells in the bone marrow. MM is 
the second most common cancer of the blood, accounting for 13% of haematological 
malignancies1, with around 3000 new cases a year in the UK2. The disease is often associated 
with the disruption of the bone marrow environment, osteolytic bone lesions, renal disease,  
immuno-deficiency and an increase in chemokine levels. Although the cause of the disease is 
unknown, many cases arise from the asymptomatic condition monoclonal gammopathy of 
uncertain significance (MGUS), which is considered a pre-malignant stage of the disease3,4. The 
rate of progression from MGUS to MM is 1% a year5, a process which is thought to be 
exacerbated by the breakdown of immunosurveillance, but this remains unclear6. MM is a 
multi-step disease, consisting of relapse and plateau phases, with successive relapses becoming 
more difficult to treat, and death usually occuring within 3-5 years1. 
Although there have been many improvements in treatments for MM, it is still considered an 
incurable disease, and so there is desperate need for effective novel treatments. Examples of 
such treatments include peripheral blood stem cell transplantation (PBSCT) and the use of 
pharmacological agents such as thalidomide, bortezomib, and lenalidomide7. A common 
approach for the targeting of tumours for immunotherapy is through the recognition of tumour 
antigens, either common to a range of tumours (tumour associated antigens, TAA) or to a 
specific malignancy (tumour specific antigens, TSA). A range of TAAs expressed on MM cells 
have been discovered, such as Wilms Tumour 1 (WT1)8, MUC19 and idiotype protein10. The 
expression of these proteins is not exclusive to tumour tissue however, and so effective T-cell 
immunity towards these antigens may result in healthy tissue damage11. A group of TSAs whose 
expression is limited to transformed cells were discovered on MM cells, which have since been 
identified as cancer testis antigens (CTA). This therefore means that immunotherapeutic 
approaches targets CTAs would not be effective against host tissue, and be specifically aimed 
towards cancerous cells. 
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Cancer Testis Antigens are Expressed on Multiple Myeloma Cells 
CTAs are a large group of proteins whose expression is restricted to the testis and the placenta 
in adults, where their functions are largely unknown12. CTAs are also expressed on a wide range 
of tumours, such as melanoma, lung cancer and ovarian cancer (reviewed in 13). The exact role 
played by CTAs in the progression and maintenance of cancers is currently unknown. The 
expression of CTAs on MM cells was first demonstrated by van Baren et al.  in 1999 by IHC and 
RTPCR approaches14. The group detected a significant expression of genes of the MAGE, BAGE, 
GAGE, and LAGE-1/NY-ESO-1 families in a high proportion of bone marrow samples from 
patients with advanced MM14. CTAs were then identified as potential T cell targets in 2000, 
when it was observed that a MAGEA3 peptide, presented by HLA-DP4 on tumour cells was 
capable of eliciting a cytolytic CD4+ response15. 
Expression of CTAs in adults is limited to the immunologically privileged site of the testis, and 
are not expressed in somatic tissue16. Immune privileged sites are able to tolerate the induction 
of antigens without the induction of an inflammatory response, a mechanism thought to 
protect key tissues from potentially harmful immune interactions. As a result of this, tolerance 
is not established to CTAs during development, and so they are immunogenic when expressed 
in adult tissues because they are not recognised as self-proteins. Expression of CTAs is 
epigenetically controlled, and it is thought to be the breakdown of this epigenetic control via 
demethylation, a common feature in many cancers17, which leads to CTA expression. 
CTA Specific CD8+ T Cells are Detected in Multiple Myeloma Patients 
MM cells express a range of CTA proteins, which are found exclusively on cancerous tissue, and 
to which immune system has not become tolerant to. It would therefore be expected that host 
immune responses would be raised to these antigens, and lymphocytes specific for CTA 
epitopes could be detected experimentally. 
Experiments conducted by Goodyear et al. in 2005 detected specific CD8+ T cell responses to 12 
peptide epitopes from a range of CTAs in MM patients. CTA specific CD8+ T cells were isolated 
from 15 out of 37 patients, ranging between 0.0004% and 0.1% of the total CD8+ population18. 
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CTA specific CD8+ T cells were isolated from these patients and cloned, and one such clone for 
the B7 restricted MAGE-A1289-298 (RVRF) epitope shows high avidity for, and is capable of killing, 
MAGE-A1 expressing myeloma cell lines19. 
The magnitude of the CTA specific CD8+ T cell response was also found to closely correlate with 
clinical progression, with the magnitude of CTA specific responses coinciding with decreases in 
paraprotein during recovery phases of the disease. During relapses, the magnitude of the 
response has also been shown to increase. Patients who demonstrated CTA specific T cell 
responses also have improved clinical outcome, with a hazard ratio between CTA positive and 
negative groups is 0.457, indicating a significant increase in survival in CTA CD8+ positive 
patients19. 
Despite these ex vivo responses, CD8+ CTA specific T cells are not capable of clearing the 
tumour, and do not ultimately prevent patient death. Therefore, the strong correlations 
between expanded CTA specific CD8+ T cell population and clinical status may just be a 
response to the tumours progression and status, while not being able to elicit an effective 
immune response.  
This is an interesting finding, as ex vivo studies have shown CTA specific CD8+ T cells have a high 
avidity for, and are capable of killing CTA expressing myeloma cell lines, and yet in vivo they 
seem to be incapable of mounting an immune response to, and ultimately clear the tumour. A 
possible reason for this is that a common association with MM is global immune dysregulation 
of the cellular immune response, and so any potential anti-tumour immune responses may be 
repressed by this immune dysfunction20. 
Multiple Myeloma Patients Exhibit Global Immune Dysfunction 
An essential factor for the development maintenance of MM is the tumour microenvironment 
in the BM. This is maintained by interactions between the bone marrow stroma, myeloma 
plasma cells and immune cells via adhesion molecules, cytokines and chemokines, creating an 
immunologically hostile microenvironment, while simultaneously promoting tumour growth. 
This microenvironment promotes tumour cell survival, development of drug resistance, 
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angiogenesis and disordered bone metabolism20. Various interactions are shown to decrease 
the host’s immune response, such as by inadequate presentation via MHC and co-stimulatory 
pathways, as well as promotion of regulatory T cells (Treg) by the production of TGF-β
20. 
It is well documented that MM patients exhibit global immune dysfunction, a status which not 
only promotes the growth and development of the tumour and chemotherapy resistance, but 
also leads to increased morbidity and mortality from infections20. Examples of immune 
dysregulation include hypogammaglobulinemia, impaired lymphocyte function and 
neutropenia20. Impairment of the cellular immune response is well documented and plays a key 
role in the maintenance of disease. For example, a decrease in the number of CD4+ and CD8+ T 
cells correlates with decreased survival rates, indicating a link between cellular immune 
response and the control of the disease. Similarly, positive clinical responses are observed 
following the dose of infused lymphocytes, and lymphocyte recovery phases following 
peripheral blood stem cell transplantation (PBSCT)21. Other T cell aberrations include an 
inversion of both the CD4+ and CD8+ ratio and Th1:Th2 CD4
+ ratio. Abnormal T cell  functional 
responses are also common in MM patients, as it has been frequently observed that key 
molecules in T cell signalling, such as CD3ζ and ZAP7022, are down regulated in T cells from MM 
patients. 
Chemokines Play a Key Role in the Progression and Maintenance of MM 
Another key characterisation of MM is the increase in global chemokine levels, which have 
been shown to contribute towards MM proliferation and survival23. Chemokines and their 
receptors play key roles in the migration, homing and development of T cells.  
Chemokines are typically small secreted proteins, with a highly conserved secondary structure. 
Chemokine receptors are a diverse group of transmembrane G protein-coupled receptors which 
interact with their chemokine ligands. In humans, there are currently 44 chemokines and 17 
chemokines receptors which have been characterised24. Unpublished data from Goodyear et al. 
show that there are global alterations in the distribution of the chemokine receptors CCR4 and 
CXCR3 between T cell subsets in the BM and PB. There was also found to be an increase in the 
expression of CCR4 and CXCR3 ligands in the BM of MM patients. Ultimately, this change in 
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chemokine gradients within the tumour microenvironment leads to an alteration in the 
distribution of T cell subsets between the BM and blood in MM patients. 
This dysregulation in chemokine receptor distribution may contribute towards to 
immunologically impaired status of MM patients, although its exact role has not yet been 
determined. 
Does Dysregulation of Chemokine Receptor Expression on CTA Specific CD8+ T Cells 
Inhibit their Function in vivo? 
Previous research has established that CTA specific CD8+ T cells are present in a group of MM 
patients, which despite showing strong affinity and avidity towards CTA expressing myeloma 
cells in vitro, are ultimately incapable of clearing the tumour effectively in vivo.  
As a common observation in MM patients is global immune dysregulation, including aberrations 
to the cellular arm of the immune system, such as global alterations in chemokine receptors, as 
well as in chemokine receptor expression on CD8+ T cells. 
It is therefore hypothesised that the expression pattern of chemokine receptors on CTA specific 
CD8+ T cells may be inhibiting them from mounting effective immune responses against CTA 
expressing myeloma cells in vivo. Specifically, as chemokine receptors are heavily involved in 
the trafficking and localisation of T cells, it is expected that an alteration on chemokine 
receptors would result in localisation of CTA specific CD8+ T cells to sites where they are unable 
to interact directly with the cancerous tissue.  
The aim of this project therefore was to characterise the expression of the chemokine receptors 
CXCR6, CXCR4, CCR5 and CXCR3 on the surface of EBV and CMV peptide specific CD8+ T cells in 
both healthy donors and MM patients. These expressions will be compared to the expression 
profile of CTA specific CD8+ T cells in order to determine any major differences between the 
cohorts.  
It is hoped that this investigation will provide insight into the nature and function of CTA 
specific CD8+ T cells in MM patients. Increased knowledge of their homing properties, and 
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ultimately their manipulation, may open up new possibilities for much needed novel 
immunotherapeutic approaches using CTA specific CD8+ T cells in patients with MM. 
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Materials and Methods 
Patient Samples 
Patients were recruited from outpatient clinics at Heartlands Hospital. Informed written 
consent was obtained from all patients and local ethical permission (South Birmingham Local 
Regional Ethics Committee) was obtained prior to the study. Peripheral blood samples (20 mL) 
were prospectively taken from patients with multiple myeloma at various stages of disease. 
Where possible, samples were taken at monthly intervals and mononuclear cells were isolated 
by density gradient centrifugation using Lymphoprep (Nycomed, Oslo, Norway). Unless 
otherwise stated, freshly isolated cells were used in assays. Control subjects were obtained 
from healthy volunteers without a history of malignant disease. It is worth noting that due to 
the lack of information available about the samples, HDs were not able to be accurately age 
matched. However donors were matched to the typical age of disease carriers as closely as 
possible. 
Antibodies and Reagents 
Antibody Company 
Viral And CTA Screening 
CD3-PE Beckman Coulter 
CD3-FITC Beckman Coulter 
CD8-PC5 Beckman Coulter 
Memory Phenotyping 
CD45RO-ECD Beckman Coulter 
CCR7-FITC R&D Systems 
CD8 Amcyan BD Biosciecne 
Chemokine Receptors 
CXCR6-APC Biolegend 
CCR5-APC-Cy7 BD Biosciecne 
CXCR4-PerCpCy5.5 BD Biosciecne 
CXCR3-AF700 BD Biosciecne 
CTA Specific Dextramers 
MLMA-PE (A2) Immudex 
YLQL-PE (A2) Immudex 
RVRF-PE (B7) Immudex 
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Table 1: Table of surface antibodies and CTA specific Dextramers used in the Study 
(Brackets indicate HLA restriction of CTA Peptide) 
Lymphocytes were stored and washed in RPMI Media. TCS Media was used for the incubation 
of T lymphocytes and consists of RPMI, 10% Human Sera (Heat Inactivated), 200mM Glutamine and 
Penicillin Streptomycin (All Gibco-Invitrogen). A list of antibodies used through the investigation is 
shown in Table 1. 
Production of HLA-Peptide Tetramers 
HLA-peptide tetramers were generated using standard protocols25. Brieﬂy, HLA-A*0201 and 
B*0702 molecules were refolded in vitro with β2- microglobulin and peptides ELK, NLV, CLG and 
RAK. Refolded HLA-peptide monomer complexes were enzymatically biotinylated and then 
puriﬁed by gel ﬁltration and ion exchange. Monomer complexes were then multimerized using 
streptavidin-PE at a molar ratio of 4:1 (molecular process). For staining, cells were washed, 
resuspended in MACS buffer, and incubated for 15 minutes at 37°C with tetramer. 
Generation of CTA-Speciﬁc T Cell Peptide Lines 
2.5x106 freshly isolated PBMCs were resuspended in 200μl RPMI. CTA peptide was added to the 
cell suspension at a final concentration of 10μM, and incubated for 1h at 37°C for 1.5hours with 
intermittent agitation. Cells were then washed and resuspended in 1ml of RPMI +10% human 
serum containing IL7 (at 25ng/ml) and IL15 (at 2ng/ml) and transferred to a 24 well plate and 
stored at 37°C. After 5 days, 1ml of RPMI +10% human serum containing IL2 (at 40U/ml). After 
4 days, cells were washed and stained with CTA specific dextramers, as with fresh cells. 
Detection of CTA-Specific T cells using CTA Specific Dextramers 
2x107 freshly isolated PBMCs were CD8+ enriched using the CD8+ T cell isolation kit (Miltenyi 
Biotec) and the AutoMACs Pro seperator (Miltenyi Biotec), as documented in the 
documentation. The enriched population is then stained with CTA specific dextramers 
(Immudex) for 20 mins at room temperature. Cells are washed twice in MACs buffer then 
stained with the surface antibodies for 20 minutes at 4°C. Cells were then analysed by flow 
cytometry on the LSR II (BD Bioscience). 
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Statistics 
Graphs were plotted in Prism 5 (GraphPad, CA) and unless otherwise noted the histogram 
represents the mean with the error bars representing the standard error of the mean (SEM). 
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Results 
Detection of Virus Specific CD8+ T Cells in HD and MM Patients. 
In order to identify CD8+ T cells specific for CMV or EBV derived peptides in healthy donors 
(HD), the PBMCs of four donors were isolated by density gradient centrifugation and analysed 
by flow cytometry. Virus specific CD8+ T cells were identified by staining with a PE conjugated 
MHC tetramer containing one of four viral peptides, two of which were EBV derived, and two of 
CMV origin. The detected responses ranged from between 0.5% and 4.5% of the total CD8+ T 
cell population. An example of the gating strategy used to characterise these cells is shown in 
Figure 10. 
 
Figure 10: Gating Strategy for the detection of viral specific CD8 + T cells 
PBMCs were isolated from donors, stained and analysed by flow cytometry. i) Gate P1 selects single cells 
ii) gate P2 selects the lymphocyte population. iii) Gate P3 selects cells which are negative for the Viability 
Dye, which is taken up only by dead cells. iv) Gate P4 selects for CD8+ cells which have stained positively 
with viral MHC tetramer. In order to select the entire CD8+ population, P4 is extended to include the PE 
negative CD8
+
 cells also.  
Example shown for donor HD-DD stained with the NLV CMV MHC tetramer. P4=0.7% of CD8
+
 T cells. 
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Virus specific CD8+ T cell responses were also identified in MM patients by identical methods. 6 
Viral responses were detected in the cohort of MM patients, 3 EBV peptide specific responses 
and 3 CMV peptide specific responses. An example of the detection of an EBV specific response 
in a MM patient is shown in Figure 11. 
 
Figure 11: Detection of Virus Specific CD8+ T cells in MM patients. 
PBMCs were isolated and gated as in Figure 10.  
Example patient: PIN04 for the RAK EBV MHC Tetramer. P4=0.5% of CD8
+
 T cells 
Detection of CTA Specific CD8+ T cells in MM Patients 
Building on previous work by Goodyear et al. CTA specific CD8+ T cells were detected in the 
blood of MM patients by using PE conjugated CTA peptide specific dextramers. Because CTA 
responses are characteristically small18, PBMCs isolated from MM patients were enriched for 
CD8+ cells using a magnetic negative selection protocol in order to increase the concentration 
of dextramer within the assay and subsequently increase its sensitivity. The enrichment 
protocol consistently yielded population with a >90% CD8+ content. Again, because CTA 
responses are characteristically small, a negative control dextramer was used in each example, 
consisting of a PE conjugated dextramer containing either a HLA-A2 or HLA-B7 molecule bound 
to a nonsense peptide in order to account for nonspecific background staining of PBMC 
populations. Table 2 shows the samples previously characterised as having CTA specific 
responses by Goodyear et al., as well as the patients analysed in this investigation. 
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A CTA specific response was detected in one patient, out of five of the previously characterised 
as positive responders of the samples which were available during the investigation. 0.02% of 
CD8+ T-cells isolated from PIN 04 ex vivo PBMCs were specific for the CTA derived RVRF peptide. 
(Figure 12).  
In order to screen for small CTA specific responses in MM patients, a peptide line is established 
in order to expand the population of CTA specific CD8+ cells in vivo. Patient PBMCs are 
incubated for 10 days in the presence of CTA peptide and growth promoting cytokines. The 
cultures are then stained with CTA specific dextramer in order to detect a potential response. 
Unfortunately, due to limited availability of samples, it was not possible to develop a peptide 
line of patient PIN 04 in order to confirm the finding in the peptide line in vivo setting. 
Previous Studies This Project 
Patient 
Identification 
Number (PIN) 
Day Stain 10 
of TCL 
CTA Stain ex 
vivo 
Day 10 Stain of TCL CTA Stain ex vivo 
01 neg neg nd nd 
02 yes nd no samples 
03 yes nd nd neg 
04 yes yes nd yes 
05 neg neg no samples 
06 neg neg no samples 
07 neg neg no samples 
08 yes nd no samples 
09 yes nd neg nd 
10 yes yes nd nd 
11 yes yes nd neg 
12 neg neg no samples 
Table 2: Table of Patients and their CTA responses from this study and previous work by 
Goodyear et al. 
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Figure 12: Detection of CTA specific CD8+ T cells inpatient PIN 04 
Isolated PBMCs were stained with a CD8 Ab and CTA specific dextramer conjugated to PE. The left hand panel 
shows the response with a HLA-B7 control dextramer, containing a nonsense peptide. The right hand panel is 
stained with the RVRF MHC dextramer, and P4 represents 0.02% of CD8
+
 T cells 
It is for similar reasons further characterisation of other samples was not possible, as the high 
number of cells needed to perform each assay meant that there were not sufficient cells 
available to perform parallel studies.  
It is interesting to note that four patients who had previously been characterised as having CTA 
specific CD8+ responses were negative for these responses in these assays Table 2. CTA 
response levels have been shown to correlate with stages of disease progression, resulting in an 
increase and decrease in their numbers. Considering the time between the two investigations, 
the disease status may have changed, and so the CTA response may have diminished below the 
detectable threshold of the assays. 
It is important to note that the CTA response detected in PIN 04 has not been validated with 
the peptide line protocol, and represents a small number of events, 0.02% of the total CD8+ 
population. The comparisons made in the following sections using these data are therefore 
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expressed to give an indication of potentially important phenotypes in order to help to shape 
future investigations 
There is Global Dysregulation of Memory Phenotype of CD8+ T Cells in MM Patients 
In order to determine the memory phenotype of the CD8+ T cell population, samples were 
gated in a similar fashion as in Figure 10, but gate P4 was extended to include all CD8+ cells. This 
gated population was then characterised into memory phenotypes by virtue of their CCR7 and 
CD45RO expression. The percentage of cells of the total CD8+ population for each phenotype 
was then calculated(Figure 13). 
 
Figure 13: Memory Phenotype of the CD8+ Population of HD and MM patients 
A) The memory phenotype of the CD8
+
 population  was determined by their expression of CCR7 and 
CD45RO. CM= Central memory and EM = Effector Memory. B) Percentage of CD8+ cells expressing the 
memory phenotype in HD and MM patients. 
The results suggest that MM patients display a less varied distribution of memory phenotypes, 
with over 80% of CD8+ T cells being classified as TEMRA, compared to less than 60% for healthy 
donors. MM patients also express a much lower number of naive and central memory CD8+ T 
cells than healthy donors, whereas levels of effector memory cells are not significantly altered. 
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Figure 14: Gating Strategy and Characterisation of Chemokine Expression Pattern 
(A) Events isolated in gate P4 from Figure 10 are separated into one of four gates in the first panel, by virtue of 
their expression of CCR5 and CXCR6. (B) Each quadrant represents one of the four possible combinations of these 
chemokines. Each quadrant is then analysed in the subsequent panels for their expression of CXCR4 and CXCR6. 
Each of the 16 quadrants of the final four panels therefore represents one of the 16 possible combinations of the 
four chemokines CXCR4, CXCR6, CCR5 and CXCR3. This example characterises the expression pattern of HD-DD NLV 
specific CD8
+
 T cells. 
A 
B 
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There is Global Dysregulation of Chemokine Receptor Expression of CD8+ T Cells in 
MM Patients 
In order to characterise the chemokine receptor expression profile of both global and virus 
specific CD8+ T cell populations, HD and MM patient PBMCs were stained with a panel of 
fluorescently labelled antibodies specific for the chemokine receptors CXCR4, CXCR3, CXCR6 
and CCR5. Populations of either all CD8+ T cells or PE stained viral specific peptides where then 
characterised for their chemokine receptor expression profile. Figure 14 demonstrates the 
gating strategy used. In order to include the global CD8+ T cell population, gate P4 from Figure 
10 was extended to include all CD8+ cells. 
The expression levels of the chemokine receptors CXCR6, CXCR4, CXCR3 and CCR5 was 
determined on both the PB CD8+ T cell population and viral/CTA peptide specific CD8+ T cells in 
both HD and MM patients. The percentage of cells in the global CD8+ T cell population 
expressing each of the chemokines previously mentioned was calculated and is shown in Figure 
15. 
 
Figure 15: Expression levels of Chemokine Receptors on CD8+ Cells in HD and MM 
Patients 
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CXCR6 expression is low on the CD8+ T cell population of both HD and MM patients, being 
expressed on less than 5% of cells in each case. There is no significant difference in the 
expression of CCR5 between the two cohorts, with levels consistently between 30% and 40%. 
The results show a significant decrease in the expression levels of CXCR3 and CXCR4 on the 
global CD8+ T cell population. The percentage of cells positive for CXCR4 decreases from 30% to 
10% in MM patients. 
MM Patients Exhibit Altered Chemokine Receptor Expression on Viral Specific CD8+ T 
Cells 
As well as dysregulation of the chemokine receptors expressed on the global CD8+ T cell 
population, their expression is uniquely altered on CMV and EBV viral peptide specific CD8+ T 
cells in MM patients. EBV peptide specific CD8+ T cells exhibit decreased expression of CXCR3 
compared to HD controls. Levels of CXCR3 on CMV peptide specific cells are not affected 
however (Figure 16A). 
CMV specific CD8+ T cells show a significant decrease in CXCR4 levels compared to HD controls, 
whereas conversely MM patients appear to have increased levels of CXCR4 on CMV specific 
CD8+ T cells, however this observation is not statistically significant. Similarly to the global CD8+ 
T cell population, CCR5 levels do not differ between HD and MM patients.  
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Figure 16: Chemokine Receptor Expression profile of Viral  and CTA specific CD8+ T cells 
In order to investigate the different combinations of chemokine receptors on viral/CTA peptide 
specific CD8+ T cells between HD and MM patients, combinations of CXCR4, CCR5 and CXCR3 
were analysed. CXCR6 was excluded from the analysis because its expression on PB CD8+ T cells 
in both HD and MM samples is very low (Figure 15). 
Combinations of these chemokines on viral peptide specific CD8+ T cells were analysed for 
combinations which showed the biggest differences between the two populations, and other 
potentially important combinations (Figure 16B).  
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The most common phenotype across both of the cohorts is CXCR4-CCR5-CXCR3-, meaning the 
majority of cells do not express any of the three chemokines analysed. Several combinations of 
chemokine receptors are different for each of the cohorts however, for example the percentage 
of cells expressing the CXCR4-CCR5+CXCR3+ phenotype is lower in MM patients than in controls, 
whereas the expression of CXCR4 single positive cells are increased in MM patients, despite 
global CXCR4 levels being shown to be decreased in MM patients. 
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Discussion 
A proportion of MM patients possess a subset of CD8+ T cells which are specific for CTA derived 
peptides expressed on the surface of MM cells. Despite these cells eliciting an effective immune 
response against CTA expressing myeloma cell lines in vitro, effective in vivo responses have yet 
to be documented. The further characterisation of these CTA specific responses in MM patients 
is an important area to explore, as their manipulation may potentially lead to improvements in 
the immunotherapeutic approaches used to treat the disease. 
A common observation in MM patients is global immune dysregulation, and the progression of 
disease appears to bring about changes in chemokine expression levels, and certain chemokine 
receptors on CD8+ T cells. Studies have shown that CTA specific T cells are enriched in the PB of 
MM patients, with reduced numbers in the BM, the site of the tumour. The disruption of 
chemokine and chemokine receptor expression gradients between the BM and PB may be a 
technique employed by the tumour in order to divert potentially anti-tumour CD8+ T cells away 
from the tumour site. 
In order to explore this hypothesis further, the aim of this investigation was to characterise the 
chemokine receptor expression profile of CTA specific CD8+ T cells in MM patients, and 
compare them with the expression profile of viral peptide specific CD8+ T cells from HD and MM 
patients. Although only one CTA response was detected in the investigation, the chemokine 
receptor expression profile of global as well as viral specific CD8+ T cells  was analysed in HD 
and MM patients. It was found that globally, CXCR4 and CXCR3 levels are reduced on CD8+ T 
cells in MM patients, as well as unique alterations in chemokine receptor expression of EBV and 
CMV specific CD8+ T cells between the two cohorts. It is hoped that these finding will shape 
further research into this area, and ultimately lead to the better understanding of these 
potentially therapeutically useful CTA specific CD8+ T cells in MM patients. 
Detection of Viral Peptide and CTA specific CD8+ T Cells in HD and MM Patients 
CD8+ T cells specific for either virus derived peptides or CTA peptides were identified in HD and 
MM patients. Six virus specific responses were detected in the MM patient cohort and 4 in the 
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HD cohort, with half of each being specific for EBV, and the other half for CMV peptides. It 
would be interesting to determine if there is any significant differences between the response 
levels of the two groups of peptides between the two cohorts, a the progression of the disease 
may alter the levels of specific CD8+ responses, some of which may have anti-tumour 
properties, as a method of protecting the tumour. There is a great variation however between 
responses over a cohort of patients, and even between the same patients over time, so in order 
to determine this, a much larger number of samples would be required. For this reason, no 
conclusion was drawn in this in investigation. 
MM Patients Display an Exhausted Memory Phenotype on CD8+ T Cells 
The memory phenotype of T cells is important in determining their potential responses, as well 
as playing a key role in their distribution and localisation. Data collected in this investigation 
suggest that MM patients have a less diverse repertoire of CD8+ T cells compared to HD 
controls. In HD controls, 20% of the PB CD8+ T cells exhibit the naïve phenotype of CD45RO- 
CCR7+. These naïve cells have yet to encounter their cognate antigen, and so are trafficked to 
the lymph node by virtue of their CCR7 expression, where they are presented with antigen by 
antigen presenting cells (APCs). Within the MM cohort however, a significantly smaller 
proportion of the CD8+ population (less than 3%) are naïve. The majority of the CD8+ T cells in 
MM patients are TEMRA cells, which have already been exposed to antigen, and so are 
therefore unable to contribute towards a response to newly induced antigens. This 
combination of cells represents an immunologically exhausted immune phenotype, resulting in 
reduction in naïve CD8+ cells will lead to the host being less able to mount effective immune 
responses to newly induced antigens, potentially leaving an infection or tumour to persist and 
spread unchecked by the cellular immune response. This alteration may be a technique 
employed by the tumour in order to reduce the host’s ability to respond to rapidly changing 
tumour antigens, ultimately allowing the tumour to progress unhindered by the immune 
system. This data builds on previous findings that MM patients exhibit monoclonal expansions 
of subsets of T-cells, which would lead to a decrease in the numbers of other subsets, due to 
the limited habitable niche available, ultimately leading to a reduced ability to adapt to new 
immunogenic threats. This phenomenon is also observed during the ageing process. For 
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example, there are expansions of CMV specific subpopulations of T cells I older patients, which 
is known to decrease the host’s ability to adapt to new antigens. 
MM Patients Show Reduction of CXCR3 and CXCR4 expression on CD8+ T Cells in the 
Blood 
Chemokine receptors on T cells provide a central role in the trafficking of cells around the body 
and to the tissues where they are required, based on the distribution of their ligands. This 
investigation found that CD8+ T cells in PB of MM patients express less CXCR4 and CXCR3 on 
their surface than equivalent cells in HD controls. Combined with the data from the 
unpublished studies by Goodyear et al. which have shown an increase in the expression of 
CXCR3 ligands in the BM of MM patients, this suggests the distribution of CXCR3 and its ligands 
may contribute towards the alteration in the trafficking of T cells between the BM and PB. 
The decrease in CXCR3 expressing CD8 T cells in the blood may represent skewing of the 
distribution of these T cells towards the BM, as CXCR3 ligands are increased there in MM. An 
alternative interpretation is that CXCR3 and CXCR4 are down regulated on the surface of T cells 
in order to reduce their ability to home to the site of the tumour in the BM, hence shielding the 
tumour from these cells.  
In order to explore these finding further, it would be necessary to obtain matched BM samples 
from these patients, and compare the proportion of CXCR3 and CXCR4 expressing T cells 
between the BM and blood of the two cohorts of HD and MM patients. An increase in CXCR3 
and CXCR4 expressing CD8+ T cells in the BM would suggest that the BM is recruiting these cells, 
potentially as a method to combat the tumour. 
MM Status Effects the Chemokine Expression Profile of CMV and EBV Viral Peptide 
Specific CD8+ T Cells Differently 
CD8+ T cells specific for different virus derived peptides express a unique pattern chemokine 
receptors, and are also affected differently by MM status. Patients with MM appear to increase 
CXCR4 expression on EBV peptide specific CD8+ T cells, whereas CXCR3 expression is decreased. 
Conversely, CXCR4 expression is decreased on CMV specific CD8+ T cells in MM patients. 
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This differential alteration between specific CD8+ T cells in the same cohorts indicates that MM 
status can effect different CD8+ subsets in unique ways. This indicates that MM may be able to 
selectively recruit and dismiss certain subsets of CD8+ T cells which would benefit the tumours 
survival and progression. For example, CTA specific CD8+ T cells may be exclusively excluded 
from the tumour site, perhaps by a decrease in chemokine receptors, whose cognate ligand 
levels are increased in the BM, such as CXCR3. 
Characterisation of CTA Specific CD8+ Responses in MM Patients 
CTA specific CD8+ T cells effectively target and kill CTA expressing myeloma cells in vitro, yet 
effective responses in vivo have not been observed. CTA responses are characteristically low, 
usually representing between 0.0004% and 0.1% of the total CD8+ population in a subset of MM 
patients. In this short study, a limited number of MM samples were available, with limitations 
on clinical availability of the patients. Samples from 17 MM patients were collected during the 
course of the study, many of which had previously been characterised as not having CTA 
specific CD8+ response. As a result of this, only one CTA response was detected and 
characterised. Unfortunately subsequent samples were not obtained in order the confirm the 
findings by means of repeats or the establishment of peptide lines in order to expand any 
potential responses. 
Interestingly, four patients who had previously been characterised as positive responders for 
CTA specific CD8+ T cells failed to show a response in these assays. It has been shown that CTA 
response levels can change and track the stage of the disease, which fluctuates between 
plateau and relapse phases. As such, responses detected previously could likely disappear, or 
reduce to a level not detectable due to the sensitivity of the assays used. 
Because of these reasons, no significant comment can be made on the responses observed, as 
they represent an unconfirmed subset of CTA specific T cells in one patient. In order to expand 
upon this investigation to be able to characterise these CTA specific responses, greater 
numbers of patient samples would be required. These patients are available to the group, and 
have an extensively documented clinical history, and so are ideal for the study. It was only time 
restraints and clinical availability which limited the scope of this investigation, and the assays 
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and techniques used have been refined and demonstrated to work effectively. Therefore, given 
more time, expansion of this investigation would hopefully yield significant , novel data in this 
area. 
Future Directions 
In order to expand upon the foundations laid by this investigation, several approaches have 
been considered. Firstly, in order to improve the quality and reliability of data obtained in this 
study, a greater number of patient and donor samples is required. This would allow the 
characterisation of multiple CTA specific T cell responses, generating statistically robust data 
which can be analysed and reliably compared to controls. 
As mentioned previously, obtaining paired BM samples from patients and controls would allow 
for the comparison between the chemokine receptor expression patterns on CD8+ T cells 
between the two sites. This would allow for us to determine the distribution of these subsets 
see if a particular chemokine receptor expression profile is favoured at each site. This increased 
understanding of the potential role of chemokine receptors in the localisation of CTA specific 
CD8+ T cells in MM.  
Another further direction to expand upon this research would be to obtain samples from a 
cohort of MGUS patients. MGUS is the pre-malignant a-symptomatic precursor of MM, and is 
currently poorly understood in terms of risk factors and triggers for progression into malignant 
disease. Exploration of the role of CTA specific CD8+ T cells in MGUS and its progression into 
MM may lead to an understanding of the significance of these responses and their role in the 
maintenance of disease. Trafficking of T cells which have a role in immune-surveillance or 
inhibition of tumour growth make play a key role in the development of the disease, and 
increased understanding may shed some light on potential therapies to inhibit this transition. 
Concluding Remarks 
MM is the second most common cancer of the blood, accounting for 13% of haematological 
malignancies1, with around 3000 new cases a year in the UK2. MM is an incurable disease, and 
although many treatments are currently in use in the clinic, novel curative treatments are 
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desperately needed. There is currently massive interest in the area immunotherapy as a 
method for treating a range of cancers, with both trail and clinical applications proving 
successful. There is a growing interest in the characterisation and potential manipulation of CTA 
specific CD8+ T cells in MM patients, and the understanding of their potential role in persistence 
of the disease is key to this development. Recent evidence has suggesting that the localisation 
and trafficking of these cells, as a result of chemokine and chemokine receptor expression may 
be an important factor in their lack of ability to mount an effective immune response against 
the tumour in vivo. 
This investigation has aimed to build on these findings, and has refined and expanded upon 
techniques to analyse chemokine receptor expression patterns antigen specific T cells in 
patients, such as viral peptide and CTA specific CD8+ T cells. The data collected in this 
investigation suggest that globally, MM patients have lower CXCR3 and CXCR4 expression on 
CD8+ T cells in PB, likely as the cells expressing high levels of CXCR3 have been trafficked to the 
BM, where CXCR3 ligand expression is increased in MM. This study also found that MM effects 
the chemokine expression profile of antigen specific CD8+ T cells in different ways, indicating 
that perhaps CTA specific T-cells may be specifically trafficked in a manner which protects the 
tumour site from their potentially power anti-tumour functions. 
Ultimately it is hoped that this project will aid in the development of future research into this 
field, leading to the characterisation and manipulation of these responses to improve clinical 
outcomes of MM patients. 
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